Sector News

Pfizer’s Viagra keeps generics at bay in China, with sales up 47%

May 5, 2015
Life sciences
Pfizer’s Viagra sales may be suffering from generic rivals in Europe. But the brand is still going gangbusters in China, helping to soften the blow.
 
Viagra sales in that country jumped 47% last year despite generic competition, according to IMS Health data cited by Bloomberg. That performance helped offset declines in other international markets. Changing attitudes toward sex may be helping, as the country allows more discussion on sexual health and people pay more attention to their sex lives, Max Xiaonian, deputy director of the China Sexology Association, told the news outlet.
 
But Pfizer’s education push has helped that discussion along–and kept consumers loyal to the brand, Bloomberg notes. The company in 2013 kicked off a series of awareness campaigns to get people to talk about erectile dysfunction medicines, and last year sponsored a survey about the sexual health of more than 10,000 Chinese professionals, Bloomberg reports. Pfizer also rolled out a smartphone app that offers sex tips, such as keeping cell phones turned off during sex. Altogether, the company estimates its educational efforts last year garnered 9 billion media impressions in China.
 
This is good news for Pfizer, as it continues to capitalize on a growing ED market in China. About 28% of Chinese men between the ages of 30 to 60 reported having erectile dysfunction, suggesting a potential urban patient population for the drug of 68 million, Bloomberg reports. And Viagra holds almost two-thirds of the ED market in China, giving it an edge on competitors such as Eli Lilly’s Cialis.
 
Strong Chinese sales for Viagra could help Pfizer offset generic competition in the U.S. when it comes along. The company struck a deal in 2013 with Teva Pharmaceutical, allowing the Israeli drugmaker to launch a U.S. copycat in December 2017. And just last week, it inked a similar settlement with Mylan. Pfizer is already facing generic competition in China and Europe, where Viagra is already off-patent.
 
By Emily Wasserman
 

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend